;PMID: 6205121 ;source_file_2863.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..36] = [t:0..36] ;1)sentence:[e:42..142] = [t:42..142] ;2)section:[e:146..191] = [t:146..191] ;3)sentence:[e:195..332] = [t:195..332] ;4)sentence:[e:333..519] = [t:333..519] ;5)sentence:[e:520..720] = [t:520..720] ;6)sentence:[e:721..980] = [t:721..980] ;7)sentence:[e:981..1184] = [t:981..1184] ;8)sentence:[e:1185..1324] = [t:1185..1324] ;9)section:[e:1328..1372] = [t:1328..1372] ;section 0 Span:0..36 ;J Neural Transm. 1984;59(4):309-17. (SEC (FRAG (NNP:[0..1] J) (NNP:[2..8] Neural) (NNP:[9..15] Transm) (.:[15..16] .) (CD:[18..22] 1984) (CD:[22..24] ;5) (CD:[24..25] 9) (NN:[25..26] -LRB-) (NN:[26..27] 4) (NN:[27..28] -RRB-) (::[28..29] :) (CD:[29..32] 309) (CD:[32..35] -17) (.:[35..36] .))) ;sentence 1 Span:42..142 ;Herpes simplex virus persistence in mouse neuroblastoma (C 1300) cell ;cultures: role of interferon. ;[84..97]:malignancy-type:"neuroblastoma" ;[131..141]:gene-protein:"interferon" (SENT (NP-HLN (NP (NP (NML (NML (NN:[42..48] Herpes) (NN:[49..56] simplex)) (NN:[57..62] virus)) (NN:[63..74] persistence)) (PP (IN:[75..77] in) (NP (NN:[78..83] mouse) (NN:[84..97] neuroblastoma) (PRN (-LRB-:[98..99] -LRB-) (NP (NN:[99..100] C) (CD:[101..105] 1300)) (-RRB-:[105..106] -RRB-)) (NN:[107..111] cell) (NNS:[112..120] cultures)))) (::[120..121] :) (NP (NP (NN:[123..127] role)) (PP (IN:[128..130] of) (NP (NN:[131..141] interferon)))) (.:[141..142] .))) ;section 2 Span:146..191 ;Dawson GJ, Mowshowitz SL, Cohen R, Elizan TS. (SEC (FRAG (NNP:[146..152] Dawson) (NNP:[153..155] GJ) (,:[155..156] ,) (NNP:[157..167] Mowshowitz) (NNP:[168..170] SL) (,:[170..171] ,) (NNP:[172..177] Cohen) (NNP:[178..179] R) (,:[179..180] ,) (NNP:[181..187] Elizan) (NNP:[188..190] TS) (.:[190..191] .))) ;sentence 3 Span:195..332 ;The Mp strain of herpes simplex virus type 1 (HSV1) induced a persistent ;infection in the mouse C 1300 neuronal cell line (clone N 115). (SENT (S (NP-SBJ (NP (DT:[195..198] The) (NN:[199..201] Mp) (NN:[202..208] strain)) (PP (IN:[209..211] of) (NP (NP (NML (NML (NN:[212..218] herpes) (NN:[219..226] simplex)) (NN:[227..232] virus)) (NN:[233..237] type) (CD:[238..239] 1)) (NP (-LRB-:[240..241] -LRB-) (NN:[241..245] HSV1) (-RRB-:[245..246] -RRB-))))) (VP (VBD:[247..254] induced) (NP (DT:[255..256] a) (JJ:[257..267] persistent) (NN:[269..278] infection)) (PP-LOC (IN:[279..281] in) (NP (DT:[282..285] the) (NN:[286..291] mouse) (NML (NN:[292..293] C) (CD:[294..298] 1300)) (JJ:[299..307] neuronal) (NN:[308..312] cell) (NN:[313..317] line) (PRN (-LRB-:[318..319] -LRB-) (NP (NN:[319..324] clone) (NN:[325..326] N) (CD:[327..330] 115)) (-RRB-:[330..331] -RRB-))))) (.:[331..332] .))) ;sentence 4 Span:333..519 ;C 1300 cultures infected at an MOI of 0.01 or 0.001 survived the initial ;infection and continued to produce infectious virus and viral antigens for ;185 days and 31 days, respectively. ;[464..478]:gene-protein:"viral antigens" (SENT (S (NP-SBJ-1 (NP (NML (NN:[333..334] C) (CD:[335..339] 1300)) (NNS:[340..348] cultures)) (VP (VBN:[350..358] infected) (NP (-NONE-:[358..358] *)) (PP (IN:[359..361] at) (NP (NP (DT:[362..364] an) (NN:[365..368] MOI)) (PP (IN:[369..371] of) (NP (CD:[372..376] 0.01) (CC:[377..379] or) (CD:[380..385] 0.001))))))) (VP (VP (VBD:[386..394] survived) (NP (DT:[395..398] the) (JJ:[399..406] initial) (NN:[407..416] infection))) (CC:[417..420] and) (VP (VBD:[421..430] continued) (S (NP-SBJ-1 (-NONE-:[430..430] *)) (VP (TO:[432..434] to) (VP (VB:[435..442] produce) (NP (NP (NP (JJ:[443..453] infectious) (NN:[454..459] virus)) (CC:[460..463] and) (NP (JJ:[464..469] viral) (NNS:[470..478] antigens))) (PP-TMP (IN:[479..482] for) (NP (NP (CD:[483..486] 185) (NNS:[487..491] days)) (CC:[492..495] and) (NP (CD:[496..498] 31) (NNS:[499..503] days))))) (,:[503..504] ,) (ADVP (RB:[506..518] respectively))))))) (.:[518..519] .))) ;sentence 5 Span:520..720 ;Viral antigens were not detected in cultures no longer producing infectious ;virus; these "cured" cultures had comparable susceptibility to reinfection ;with HSV as previously uninfected C 1300 cells. ;[520..534]:gene-protein:"Viral antigens" ;[597..602]:malignancy-type:"virus" ;[678..681]:malignancy-type:"HSV" (SENT (S (S (NP-SBJ-1 (JJ:[520..525] Viral) (NNS:[526..534] antigens)) (VP (VBD:[535..539] were) (RB:[540..543] not) (VP (VBN:[544..552] detected) (NP-1 (-NONE-:[552..552] *)) (PP-LOC (IN:[553..555] in) (NP (NP (NNS:[556..564] cultures)) (VP (ADVP-TMP (RB:[565..567] no) (JJR:[568..574] longer)) (VBG:[575..584] producing) (NP (JJ:[586..596] infectious) (NN:[597..602] virus)))))))) (::[602..603] ;) (S (NP-SBJ (DT:[604..609] these) (``:[610..611] ") (VBN:[611..616] cured) ('':[616..617] ") (NNS:[618..626] cultures)) (VP (VBD:[627..630] had) (NP (NP (JJ:[631..641] comparable) (NN:[642..656] susceptibility)) (PP (TO:[657..659] to) (NP (NP (NN:[661..672] reinfection)) (PP (IN:[673..677] with) (NP (NN:[678..681] HSV))))) (PP (IN:[682..684] as) (NP (ADJP (RB:[685..695] previously) (JJ:[696..706] uninfected)) (NML (NN:[707..708] C) (CD:[709..713] 1300)) (NNS:[714..719] cells)))))) (.:[719..720] .))) ;sentence 6 Span:721..980 ;While significant amounts of interferon were produced by C 1300 cells when ;challenged with Newcastle Disease Virus (NDV) or when treated with poly I:C, ;HSV-induced interferon could not be detected in either the acutely or ;persistently infected cell lines. ;[751..761]:gene-protein:"interferon" ;[888..898]:gene-protein:"interferon" (SENT (S (SBAR-ADV (IN:[721..726] While) (S (NP-SBJ-1 (NP (JJ:[727..738] significant) (NNS:[740..747] amounts)) (PP (IN:[748..750] of) (NP (NN:[751..761] interferon)))) (VP (VBD:[762..766] were) (VP (VBN:[767..775] produced) (NP-1 (-NONE-:[775..775] *)) (PP (IN:[776..778] by) (NP-LGS (NML (NN:[779..780] C) (CD:[781..785] 1300)) (NNS:[786..791] cells))) (SBAR-ADV (SBAR (WHADVP-2 (WRB:[792..796] when)) (S (NP-SBJ-4 (-NONE-:[796..796] *)) (VP (VBN:[797..807] challenged) (NP-4 (-NONE-:[807..807] *)) (PP-MNR (IN:[808..812] with) (NP (NML (NNP:[814..823] Newcastle) (NNP:[824..831] Disease)) (NNP:[832..837] Virus) (NP (-LRB-:[838..839] -LRB-) (NN:[839..842] NDV) (-RRB-:[842..843] -RRB-)))) (ADVP-TMP-2 (-NONE-:[843..843] *T*))))) (CC:[844..846] or) (SBAR (WHADVP-3 (WRB:[847..851] when)) (S (NP-SBJ-5 (-NONE-:[851..851] *)) (VP (VBN:[852..859] treated) (NP-5 (-NONE-:[859..859] *)) (PP-MNR (IN:[860..864] with) (NP (NN:[865..869] poly) (NN:[870..871] I) (SYM:[871..872] :) (NN:[872..873] C))) (ADVP-TMP-3 (-NONE-:[873..873] *T*)))))))))) (,:[873..874] ,) (NP-SBJ-6 (ADJP (NN:[875..878] HSV) (HYPH:[878..879] -) (VBN:[879..886] induced)) (NN:[888..898] interferon)) (VP (MD:[899..904] could) (RB:[905..908] not) (VP (VB:[909..911] be) (VP (VBN:[912..920] detected) (NP-6 (-NONE-:[920..920] *)) (PP-LOC (IN:[921..923] in) (NP (CC:[924..930] either) (DT:[931..934] the) (NML (NML (ADJP (RB:[935..942] acutely) (ADJP-7 (-NONE-:[942..942] *P*))) (NML-8 (-NONE-:[942..942] *P*))) (CC:[943..945] or) (NML (ADJP (RB:[946..958] persistently) (ADJP-7 (VBN:[959..967] infected))) (NML-8 (NN:[969..973] cell) (NNS:[974..979] lines))))))))) (.:[979..980] .))) ;sentence 7 Span:981..1184 ;The persistent state was not significantly altered by the addition of 1,000 ;units/ml of murine interferon alpha plus beta (MuIFN alpha + beta), nor was ;it affected by the addition of antibody to MuIFN. ;[1077..1093]:gene-protein:"interferon alpha" ;[1077..1087]...[1099..1103]:gene-protein:"interferon"..."beta" ;[1105..1116]:gene-protein:"MuIFN alpha" ;[1105..1110]...[1119..1123]:gene-protein:"MuIFN"..."beta" ;[1166..1174]:gene-protein:"antibody" ;[1178..1183]:gene-protein:"MuIFN" (SENT (S (S (NP-SBJ-1 (DT:[981..984] The) (JJ:[985..995] persistent) (NN:[996..1001] state)) (VP (VBD:[1002..1005] was) (RB:[1006..1009] not) (ADVP (RB:[1010..1023] significantly)) (VP (VBN:[1024..1031] altered) (NP-1 (-NONE-:[1031..1031] *)) (PP (IN:[1032..1034] by) (NP-LGS (NP (DT:[1035..1038] the) (NN:[1039..1047] addition)) (PP (IN:[1049..1051] of) (NP (NP (CD:[1052..1057] 1,000) (NNS:[1058..1063] units)) (PP (SYM:[1063..1064] /) (NP (NN:[1064..1066] ml))) (PP (IN:[1067..1069] of) (NP (NP (NML-2 (JJ:[1070..1076] murine) (NN:[1077..1087] interferon)) (SYM:[1088..1093] alpha)) (CC:[1094..1098] plus) (NP (NML-2 (-NONE-:[1098..1098] *P*)) (SYM:[1099..1103] beta)) (PRN (-LRB-:[1104..1105] -LRB-) (NP (NP (NML-3 (NN:[1105..1110] MuIFN)) (SYM:[1111..1116] alpha)) (SYM:[1117..1118] +) (NP (NML-3 (-NONE-:[1118..1118] *P*)) (SYM:[1119..1123] beta))) (-RRB-:[1123..1124] -RRB-))))))))))) (,:[1124..1125] ,) (CC:[1126..1129] nor) (SINV (VBD:[1131..1134] was) (NP-SBJ-4 (PRP:[1135..1137] it)) (VP (VBN:[1138..1146] affected) (NP-4 (-NONE-:[1146..1146] *)) (PP (IN:[1147..1149] by) (NP-LGS (NP (DT:[1150..1153] the) (NN:[1154..1162] addition)) (PP (IN:[1163..1165] of) (NP (NN:[1166..1174] antibody))) (PP (TO:[1175..1177] to) (NP (NN:[1178..1183] MuIFN))))))) (.:[1183..1184] .))) ;sentence 8 Span:1185..1324 ;It appears that IFN does not play an important role in the establishment ;and/or maintenance of viral persistence in this neuronal system. ;[1201..1204]:gene-protein:"IFN" (SENT (S (NP-SBJ (PRP:[1185..1187] It)) (VP (VBZ:[1188..1195] appears) (SBAR (IN:[1196..1200] that) (S (NP-SBJ (NN:[1201..1204] IFN)) (VP (VBZ:[1205..1209] does) (RB:[1211..1214] not) (VP (VB:[1215..1219] play) (NP (DT:[1220..1222] an) (JJ:[1223..1232] important) (NN:[1233..1237] role)) (PP (IN:[1238..1240] in) (NP (NP (DT:[1241..1244] the) (NN:[1245..1258] establishment) (CC:[1259..1265] and/or) (NN:[1266..1277] maintenance)) (PP (IN:[1278..1280] of) (NP (JJ:[1281..1286] viral) (NN:[1288..1299] persistence))))) (PP (IN:[1300..1302] in) (NP (DT:[1303..1307] this) (JJ:[1308..1316] neuronal) (NN:[1317..1323] system)))))))) (.:[1323..1324] .))) ;section 9 Span:1328..1372 ;PMID: 6205121 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1328..1332] PMID) (::[1332..1333] :) (CD:[1334..1341] 6205121) (NN:[1342..1343] -LSB-) (NNP:[1343..1349] PubMed) (::[1350..1351] -) (NN:[1352..1359] indexed) (IN:[1360..1363] for) (NNP:[1364..1372] MEDLINE-RSB-)))